Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy

<p><strong>Background.</strong> Therapy for metastatic castration-resistant prostate cancer (CRPC) is a serious problem that requires significant public health care expenditures.</p><p><strong>Objective</strong>: to evaluate the cost-effectiveness of abirate...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: A. V. Rudakova, D. O. Meshkov, S. V. Mishugin
Natura: Artigo
Lingua:Russo
Pubblicazione: ABV-press 2014-11-01
Serie:Onkourologiâ
Soggetti:
castration-resistant prostate cancer
chemotherapy
docetaxel
abiraterone
survival
cost effectiveness
Accesso online:http://oncourology.abvpress.ru/index.php/oncur/article/view/383
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi